Get the Stockscreener App
8.91
1.71%
0.15
After Hours:
8.90
-0.010
-0.11%
Ocular Therapeutix Inc stock is traded at $8.91, with a volume of 2.55M.
It is up +1.71% in the last 24 hours and up +1.71% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$8.76
Open:
$8.76
24h Volume:
2.55M
Relative Volume:
0.42
Market Cap:
$1.94B
Revenue:
$51.95M
Net Income/Loss:
$-265.94M
P/E Ratio:
-6.1944
EPS:
-1.4384
Net Cash Flow:
$-216.89M
1W Performance:
+5.82%
1M Performance:
+1.71%
6M Performance:
-25.35%
1Y Performance:
+18.33%
1-Day Range:
$8.655
$9.00
1-Week Range:
$8.33
$9.43
52-Week Range:
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.91 | 1.91B | 51.95M | -265.94M | -216.89M | -1.4384 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Ocular Therapeutix (OCUL) soars 10.4% ahead of business updates - MSN
Discipline and Rules-Based Execution in OCUL Response - Stock Traders Daily
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study - Sahm
H.C. Wainwright reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
New Ocular SVP gets 300,000 stock options in inducement grant - Stock Titan
Here is why Ocular Therapeutix (OCUL) is highly favored by hedge funds - MSN
Aug EndMonth: Can Ocular Therapeutix Inc maintain its current growth rateWeekly Gains Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Large Ocular Therapeutix (OCUL) share gift to spouse disclosed - Stock Titan
William Blair reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix presents additional wet AMD trial data By Investing.com - Investing.com Australia
William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating - Moomoo
OCUL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $21 - GuruFocus
What's Going On With Ocular Therapeutix Stock Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
Positive Week 52 Data Released for Ocular Therapeutix (OCUL) - GuruFocus
Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli’s Phase 3 Design Choices? - Yahoo Finance
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD - The Manila Times
Ocular Therapeutix Presents New SOL-1 Data Reinforcing AXPAXLI's Efficacy and Durability in Wet AMD at VBS Meeting - Quiver Quantitative
Ocular Therapeutix presents additional wet AMD trial data - Investing.com
Ocular Therapeutix™ Announces Additional Positive Week 52 - GlobeNewswire
Assessing Whether Ocular Therapeutix (OCUL) Looks Undervalued After Recent Mixed Share Price Performance - Yahoo Finance
Sectors Review: Is Ocular Therapeutix Inc undervalued by DCF analysis2026 Drop Watch & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Aug Rallies: Should I invest in Ocular Therapeutix Inc before earnings2026 Pullbacks & Safe Entry Zone Tips - baoquankhu1.vn
Ocular Therapeutix Stock Surges 10% Past $9 on Fresh SOL-1 Data Presentations for AXPAXLI - International Business Times Australia
Ocular Therapeutix (OCUL) Soars 10.4% Ahead of Business Updates - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - MSN
Market Leaders: Will Ocular Therapeutix Inc stock hit new highs in YEAR - baoquankhu1.vn
Update Recap: Will Ocular Therapeutix Inc benefit from geopolitical trendsTrade Signal Summary & Verified Momentum Stock Alerts - baoquankhu1.vn
Will Ocular Therapeutix’s (OCUL) AXPAXLI Data Spotlight Redefine Its Retinal Competitive Positioning? - Sahm
Behavioral Patterns of OCUL and Institutional Flows - Stock Traders Daily
OCULAR THERAPEUTIX, INC. (OCUL) - MSN
HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Sahm
Analysis Recap: How sensitive is Ocular Therapeutix Inc to inflation2026 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn
OCUL Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds - Insider Monkey
Ocular lines up April talks on wet AMD trial data and retinal disease - Stock Titan
Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Bitget
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3%Should You Buy? - marketbeat.com
OCULAR THERAPEUTIX (01477.HK) Completes First Patient Enrollment in Phase III Clinical Trial for OT-211 - AASTOCKS.com
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 34.2% in March - MarketBeat
Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Why Ocular Therapeutix (OCUL) Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim - Sahm
What Ocular Therapeutix (OCUL)'s Single-Study FDA Bid After SOL-1 Superiority Means For Shareholders - Yahoo Finance
Vanguard reports zero holdings in Ocular Therapeutix (OCUL) - Stock Titan
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Ocular Therapeutix, Inc. (OCUL): A bull case theory - MSN
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):